Could new US investment curbs complicate China’s biotech licensing surge?
Licensing deals untouched for now, but proposed US investment rules and new Chinese export curbs may impact biotech expansion, analysts say
The US Treasury Department’s draft rules released last week would “make it much harder for Chinese biotech firms to attract direct US investment or enter joint ventures”, according to David Zhang, an analyst at policy research firm Trivium China.
US Treasury Secretary Scott Bessent added biotechnology to an outbound investment screening programme, placing a broad range of transactions involving “countries of concern”, including China, under greater scrutiny.
